Key points:
- The hottest new disruptor in food and beverage isn't a brand, a platform, or a retail format.
- Why this is different from previous health trends.
- Four scenarios for the GLP-1 food future.
The hottest new disruptor in food and beverage isn't a brand, a platform, or a retail format.
The question is no longer whether GLP-1 therapies will affect your business. The evidence on that is settled. The question is whether your strategy reflects the reality that is already forming – and whether you are positioned to lead the response or be forced into it.
Why this is different from previous health trends.
The combination of biological efficacy, accelerating drug innovation, and improving economics means the trajectory is clear, even if the exact pace remains uncertain. This isn't a fad – it's a platform shift.
Four scenarios for the GLP-1 food future.
No one can forecast with precision which of these futures will materialise. But every one of them has strategic implications – and a food business may be implicitly betting on one without having made that choice explicitly.
The GLP-1 shock: A new disruptor in the food aisle
Follow PwC Australia
